Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Q1 2016 Earnings Presentation
21 slides from Halozyme Therapeutics's earnings presentation, May 9, 2016
Slide 1: First Quarter 2016 Earnings Call
First Quarter 2016 Earnings Call May 9, 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include future product development and regul
Slide 3: Our Focus
Our Focus To discover, develop and commercialize biopharmaceuticals that target the extracellular matrix and tumor microenvironment 2
Slide 4: Two-Pillar Strategy For Growth
Two-Pillar Strategy For Growth ENHANZE™ Platform PEGPH201 Platform Licensing/Royalty Agreements Based On Investigational New Oncology Drug Proprietary Enzyme, rHuPH20 Studying pan-tumor potential O H N O CH2 CH2 O CH2 H3 C n O H N O O CH2 CH2 O CH2 n N H3 C H CH2 CH2 CH2 O O nCH3 O N H O O CH2 CH2 O
Slide 5: PEGPH20 Goal: Improve Targeting Of Co-Administered Cancer Therapies
PEGPH20 Goal: Improve Targeting Of Co-Administered Cancer Therapies 4
Slide 6: HALO-301|Pancreatic: Phase 3 Design
HALO-301|Pancreatic: Phase 3 Design Metastatic PEGPH20 + ABRAXANE® + PDA gemcitabine (PAG) Primary Endpoints: Progression-Free High-HA Survival (PFS) patients Overall Survival (OS) ABRAXANE® + gemcitabine N=420 (AG) + placebo • Randomized (2:1 PAG:AG), double-blind, placebo-controlled, global • Firs
Slide 7: Studying Pan-Tumor Potential of PEGPH20
Studying Pan-Tumor Potential of PEGPH20 PEGPH20 Study In Preclinical Phase 1 Phase 2 Phase 3 Combination Tumor with Gemcitabine and nab- Pancreatic Paclitaxel Cancer (Abraxane) Docetaxel (PRIMAL) NSCLC Pembrolizumab Gastric/ (Keytruda®) NSCLC Breast Eribulin Cancer (Halaven®) (Eisai) Additional Inve
Slide 8: Oncology Pipeline Update
Oncology Pipeline Update 7
Slide 9: PEG-ADA2 Program Highlights
PEG-ADA2 Program Highlights Adenosine: Attractive • Abnormally high levels accumulate in the TME immune • Binds to receptor checkpoints on immune cells checkpoint • Contributes to an immunosuppressive TME target PEG-ADA2: • Improved pharmacokinetics and enzyme activity An engineered • Anti-tumor res
Slide 10: HTI-1511 Anti-EGFR ADC Program Highlights
HTI-1511 Anti-EGFR ADC Program Highlights Engineered mAb with attenuated binding to human skin grafts ADC mechanism targets KRAS- or BRAF-mutated tumors in mice Utilization of next generation, Thiobridge chemistry • More homogeneous, stable Safety profile met criteria for candidate nomination Comple
Slide 11: ENHANZE Technology
ENHANZE™ Technology 10
Slide 12: ENHANZE: Our Novel Delivery Platform
ENHANZE: Our Novel Delivery Platform Potential Benefits: • Facilitate transition of IV therapies to subcutaneous administration • Reduce multiple injections • Enable large volume of biologics to be delivered subcutaneously • Reduce time required for drug administration • Life cycle management, inclu
Slide 13: ENHANZE: Our Novel Delivery Platform
ENHANZE: Our Novel Delivery Platform US / Partner Target Preclinical Phase 1 Phase 3 Approved OUS Herceptin SC OUS Mabthera SC OUS HYQVIA US HYQVIA OUS Daratumumab -- -- Rivipansel -- Bococizumab Humira -- 3 Targets -- Identified 12
Slide 14: ENHANZE Momentum: Partnerships Accelerating, Royalty Pipeline Building
ENHANZE Momentum: Partnerships Accelerating, Royalty Pipeline Building • 2 new partnerships in 2015 • Time from signing to clinic accelerating • 4 targets in clinic; new studies planned • Estimated 150 targets available that may benefit from ENHANZE 2006 2007 2012 2014 2015 Upfront $20M $10M $8M $15
Slide 15: Roche Update: Herceptin SC
Roche Update: Herceptin SC1 1) Information provided during Roche investor update (Apr. 19, 2016). 14
Slide 16: Financial Update
Financial Update 15
Slide 17: First Quarter 2016 Financial Highlights
First Quarter 2016 Financial Highlights1 $ U.S. in Millions (unaudited) 1Q 2016 1Q 2015 % Change Total Revenue $42.5 $18.7 128% Royalty Revenue $11.4 $6.8 68% Bulk rHuPH20 Sales $9.0 $6.1 48% Hylenex® recombinant $3.9 $3.8 2% Collaboration Revenue $18.2 $2.0 795% NOTE: 1) Dollar amounts and percenta
Slide 18: First Quarter 2016 Financial Highlights
First Quarter 2016 Financial Highlights1 $ U.S. in Millions, except EPS (unaudited) 1Q 2016 1Q 2015 % Change Total Revenues $42.5 $18.7 128% Total Operating Expenses $58.7 $32.6 80% Cost of Product Sales $7.8 $6.5 20% R&D Expense $40.1 $16.7 140% SG&A Expense $10.8 $9.4 15% Net Loss ($19.8) ($15.1)
Slide 19: Update: 2016 Financial Guidance
Update: 2016 Financial Guidance Previous Revised Revenue $110M to $125M $130M to $145M Operating Expenses $240M to $260M $245M to $260M Cash Flow $35M to $55M $45M to $65M Year-end Cash $140M to $160M $150M to $170M 18
Slide 20: Value Enhancing Milestones Throughout 2016
Value Enhancing Milestones Throughout 2016 Goal Target Date Initiate HALO-301|Pancreatic trial End of Q1 2016 ✓ HALO-Eisai Study in Breast Cancer Patients Initiated End of Q2 2016 Advance to Dose Expansion Phase in KEYTRUDA and PRIMAL Studies 2H 2016 (pending number of dose cohorts) Report mature da
Slide 21: First Quarter 2016 Earnings Call
First Quarter 2016 Earnings Call May 9, 2016
Halozyme Therapeutics — Q1 2016 Earnings Presentation on 6ix